Search bioRxiv⌕ Search

Biology subjects

Caldwell, K.

Publications and source records attributed to Caldwell, K..

2 recordsLinked to original sources

Chronic delivery of buprenorphine during abstinence decreases incubation of heroin seeking and neuronal activation in medial prefrontal cortex and striatum in male and female rats

Rationale and ObjectiveBuprenorphine is an FDA-approved medication for opioid addiction, but the brain regions underlying its therapeutic effects remain unknown. We previously found that chronic buprenorphine treatment decreases several relapse-related behaviors in rats. Here, we tested whether chronic buprenorphine decreases the time-dependent increase (incubation) in heroin seeking during abstinence. We also used the activity marker Fos to test whether buprenorphines inhibition of incubation of heroin seeking is associated with decreased activation of cortical and striatal regions. MethodsWe trained Oprm1-Cre rats and their wild-type littermates to self-administer heroin for 12 days (6 h/day). On abstinence Day 1, we tested for heroin seeking under extinction conditions. On Day 14, we implanted osmotic minipumps containing saline or buprenorphine (6 mg/kg/day). On abstinence Days 21-22, we tested the rats (or not tested, baseline condition) for incubation of heroin seeking, after which brains were collected for Fos immunohistochemistry. ResultsOprm1-Cre rats did not differ from wild-type littermates in heroin self-administration or non-incubated heroin seeking on abstinence Day 1. In both genotypes, chronic buprenorphine decreased incubated heroin seeking on Days 21-22. Buprenorphine also decreased incubation-related neuronal activation in several cortical areas (anterior cingulate and dorsal peduncular, but not prelimbic, infralimbic, or orbitofrontal cortex) and striatal areas (dorsolateral and dorsomedial striosomes and nucleus accumbens core, but not shell). ConclusionsChronic buprenorphine decreased incubation of heroin seeking, supporting the predictive validity of the rat model. This effect was associated with decreased neuronal activity in specific subregions of the medial prefrontal cortex and striatum.

neuroscience↗

Therapeutic genetic variation revealed in diverse Hsp104 homologs

The AAA+ protein disaggregase, Hsp104, increases fitness under stress by reversing stress-induced protein aggregation. We have engineered potentiated Hsp104 variants to antagonize proteotoxic misfolding linked to human neurodegenerative diseases. However, these Hsp104 variants can exhibit off-target toxicity, which may limit their therapeutic utility. Hsp104 is conserved among all nonmetazoan eukaryotes, which raises the possibility that natural variants might exist with enhanced, selective activity against neurodegenerative disease substrates. To assess this possibility, we screened a cross-kingdom collection of Hsp104 homologs in several yeast proteotoxicity models. We uncovered therapeutic genetic variation among several Hsp104 homologs that specifically antagonize TDP-43 or -synuclein condensate formation and toxicity in yeast, human cells, and C. elegans. Surprisingly, this variation manifested as increased passive chaperone activity, distinct from disaggregase activity, which neutralizes proteotoxicity of specific substrates. Thus, by exploring natural tuning of passive chaperone activity we elucidated enhanced, substrate-specific agents to counter proteotoxicity underlying neurodegenerative disease.

biochemistry↗